Does letrozole (aromatase inhibitor) lower prolactin levels?

Letrozole Does Not Lower Prolactin Levels

Letrozole does not directly lower prolactin levels through its mechanism of action as an aromatase inhibitor. According to the FDA drug label, letrozole specifically inhibits the aromatase enzyme to reduce estrogen biosynthesis, and plasma levels of LH and FSH were not affected by letrozole in patients, nor was thyroid function 1. The drug label makes no mention of any effect on prolactin secretion.

Mechanism and Hormonal Effects

Letrozole works by:

• Competitively inhibiting aromatase enzyme, blocking conversion of androgens to estrogens
• Suppressing estradiol, estrone, and estrone sulfate by 75-95% 1
• Not affecting adrenal steroidogenesis, including no changes in cortisol, aldosterone, ACTH, or gonadotropins (LH/FSH) 1

The FDA label explicitly documents that letrozole does not alter pituitary hormone secretion patterns in its primary mechanism.

Special Context: Male Prolactinomas

There is an important indirect relationship in a very specific clinical scenario:

In men with dopamine-agonist-resistant prolactinomas who are receiving testosterone replacement therapy (TRT), letrozole may help control prolactin levels through a different mechanism 2, 3, 4:

• Testosterone can be aromatized to estradiol
• Estradiol stimulates lactotroph cell proliferation and prolactin secretion
• This can cause prolactin levels to rise during TRT (increases of 231-396% reported) 3
• Adding letrozole blocks this testosterone-to-estradiol conversion, preventing the estrogen-mediated stimulation of prolactin secretion
• Studies show 61-93% decreases in prolactin after adding aromatase inhibitors in this specific context 3

Clinical Algorithm for This Scenario:

1. Primary treatment: Dopamine agonists (cabergoline preferred) for prolactinomas 5
2. If dopamine-agonist resistant AND hypogonadal: Consider TRT
3. If prolactin rises on TRT: Add letrozole 2.5 mg daily 3, 4
4. Monitor: Prolactin levels and tumor size every 6-12 months

Important Caveats

• This is NOT a primary treatment for hyperprolactinemia - dopamine agonists remain first-line 5
• The evidence for aromatase inhibitors in prolactinomas consists only of case reports and small case series 2, 4 - no randomized trials exist
• Letrozole's effect is indirect (blocking estrogen that would stimulate prolactin), not a direct prolactin-lowering effect
• This approach is relevant only for the narrow population of men with resistant prolactinomas on testosterone therapy

In summary: Letrozole does not lower prolactin as a primary pharmacologic effect, but may indirectly prevent testosterone-induced prolactin elevation in men with resistant prolactinomas receiving TRT.